Which has stronger valuation and earnings, CRDL or THCX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -C$42.93M -C$0.34 N/A Hydropothecary N/A N/A N/A N/A N/A

Is CRDL or THCX more profitable?

Hydropothecary's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.13% -54.15% Hydropothecary N/A N/A N/A

Do analysts recommend CRDL or TLRY?

Tilray Brands has a consensus target price of C$13.30, indicating a potential upside of 186.64%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than Cardiol Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tilray Brands 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor CRDL or TLRY?

In the previous week, Tilray Brands had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Tilray Brands and 1 mentions for Cardiol Therapeutics. Tilray Brands' average media sentiment score of 0.03 beat Cardiol Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tilray Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CRDL or CMED?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -C$42.93M -C$0.34 N/A CanniMed Therapeutics N/A N/A N/A N/A N/A

Is CRDL or CMED more profitable?

CanniMed Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.13% -54.15% CanniMed Therapeutics N/A N/A N/A

Do analysts rate WEED or CRDL?

Canopy Growth currently has a consensus target price of C$1.88, indicating a potential upside of 73.61%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than Cardiol Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor WEED or CRDL?

In the previous week, Canopy Growth and Canopy Growth both had 1 articles in the media. Canopy Growth's average media sentiment score of 0.71 beat Cardiol Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CRDL or FRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Does the media prefer CRDL or FRX?

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 1 mentions for Cardiol Therapeutics. Fennec Pharmaceuticals' average media sentiment score of 0.75 beat Cardiol Therapeutics' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fennec Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiol Therapeutics (CRDL) Competitors

C$1.65 -0.06 (-3.51%)

As of 11:39 AM Eastern

Compare

CRDL vs. THCX, TLRY, CMED, WEED, and FRX

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include Hydropothecary (THCX), Tilray Brands (TLRY), CanniMed Therapeutics (CMED), Canopy Growth (WEED), and Fennec Pharmaceuticals (FRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Hydropothecary?

Cardiol Therapeutics (TSE:CRDL) and Hydropothecary (CVE:THCX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Hydropothecary. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for Hydropothecary. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Hydropothecary'saverage media sentiment score.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Hydropothecary	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.34	N/A
Hydropothecary	N/A	N/A	N/A	N/A	N/A

0.1% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hydropothecary's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.13%	-54.15%
Hydropothecary	N/A	N/A	N/A

Summary

Cardiol Therapeutics beats Hydropothecary on 3 of the 5 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Tilray Brands?

Cardiol Therapeutics (TSE:CRDL) and Tilray Brands (TSE:TLRY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Cardiol Therapeutics has higher earnings, but lower revenue than Tilray Brands. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.34	N/A
Tilray Brands	C$963.10M	0.71	-C$183.24M	-C$1.41	N/A

0.1% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 4.4% of Tilray Brands shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Comparatively, 0.7% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.363715, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.261139, suggesting that its share price is 226% more volatile than the broader market.

In the previous week, Tilray Brands had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Tilray Brands and 1 mentions for Cardiol Therapeutics. Tilray Brands' average media sentiment score of 0.03 beat Cardiol Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tilray Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tilray Brands has a consensus target price of C$13.30, indicating a potential upside of 186.64%. Given Tilray Brands' stronger consensus rating and higher probable upside, analysts plainly believe Tilray Brands is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cardiol Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -18.92%. Tilray Brands' return on equity of -11.41% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.13%	-54.15%
Tilray Brands	-18.92%	-11.41%	-1.41%

Summary

Tilray Brands beats Cardiol Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

Cardiol Therapeutics (TSE:CRDL) and CanniMed Therapeutics (TSE:CMED) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Cardiol Therapeutics had 1 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for CanniMed Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 equaled CanniMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
CanniMed Therapeutics	Neutral

CanniMed Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.13%	-54.15%
CanniMed Therapeutics	N/A	N/A	N/A

0.1% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.34	N/A
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Cardiol Therapeutics beats CanniMed Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Canopy Growth?

Canopy Growth (TSE:WEED) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

In the previous week, Canopy Growth and Canopy Growth both had 1 articles in the media. Canopy Growth's average media sentiment score of 0.71 beat Cardiol Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Canopy Growth's return on equity of -29.85% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Cardiol Therapeutics	N/A	-180.13%	-54.15%

Canopy Growth currently has a consensus target price of C$1.88, indicating a potential upside of 73.61%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cardiol Therapeutics has lower revenue, but higher earnings than Canopy Growth. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.56	-C$1.05B	-C$0.67	N/A
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.34	N/A

Canopy Growth has a beta of 2.406513, meaning that its stock price is 141% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.363715, meaning that its stock price is 64% less volatile than the broader market.

4.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 0.1% of Cardiol Therapeutics shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by company insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Canopy Growth beats Cardiol Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Fennec Pharmaceuticals?

Cardiol Therapeutics (TSE:CRDL) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

0.1% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 15.6% of Fennec Pharmaceuticals shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cardiol Therapeutics has a beta of 0.363715, meaning that its share price is 64% less volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.816127, meaning that its share price is 282% more volatile than the broader market.

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 1 mentions for Cardiol Therapeutics. Fennec Pharmaceuticals' average media sentiment score of 0.75 beat Cardiol Therapeutics' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fennec Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Fennec Pharmaceuticals has higher revenue and earnings than Cardiol Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.34	N/A
Fennec Pharmaceuticals	C$59.22M	8.58	-C$800.44K	-C$0.12	N/A

Cardiol Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -6.21%. Fennec Pharmaceuticals' return on equity of -13.34% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.13%	-54.15%
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

Summary

Fennec Pharmaceuticals beats Cardiol Therapeutics on 12 of the 14 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$200.50M	C$12.43B	C$7.28B	C$12.63B
Dividend Yield	N/A	2.63%	2.51%	6.34%
P/E Ratio	-4.85	807.81	275.44	37.52
Price / Sales	N/A	748.21	559.80	8.41
Price / Cash	0.98	86.65	77.16	82.29
Price / Book	7.89	9.19	10.66	4.36
Net Income	-C$42.93M	C$2.84B	C$3.50B	C$299.09M
7 Day Performance	-10.81%	-3.85%	-3.65%	-0.27%
1 Month Performance	-40.43%	-7.95%	-8.06%	-2.32%
1 Year Performance	13.01%	-5.71%	2.58%	14.22%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	N/A	C$1.65 -3.5%	N/A	+17.1%	C$200.50M	N/A	N/A	18
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
TLRY Tilray Brands	1.5454 of 5 stars	C$5.13 +1.0%	C$13.30 +159.3%	-80.6%	C$758.12M	C$915.45M	N/A	3,595
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
WEED Canopy Growth	2.3931 of 5 stars	C$1.26 +0.8%	C$1.88 +48.8%	-43.8%	C$533.03M	C$293.63M	N/A	2,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CRDL) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. THCX, TLRY, CMED, WEED, and FRX

How does Cardiol Therapeutics compare to Hydropothecary?

Summary

How does Cardiol Therapeutics compare to Tilray Brands?

Summary

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

Summary

How does Cardiol Therapeutics compare to Canopy Growth?

Summary

How does Cardiol Therapeutics compare to Fennec Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. THCX, TLRY, CMED, WEED, and FRX

How does Cardiol Therapeutics compare to Hydropothecary?

Does the media favor CRDL or THCX?

Which has stronger valuation and earnings, CRDL or THCX?

Do institutionals and insiders believe in CRDL or THCX?

Is CRDL or THCX more profitable?

Summary

How does Cardiol Therapeutics compare to Tilray Brands?

Which has preferable valuation and earnings, CRDL or TLRY?

Do insiders & institutionals believe in CRDL or TLRY?

Which has more volatility and risk, CRDL or TLRY?

Does the media favor CRDL or TLRY?

Do analysts recommend CRDL or TLRY?

Is CRDL or TLRY more profitable?

Summary

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

Does the media favor CRDL or CMED?

Is CRDL or CMED more profitable?

Do insiders and institutionals have more ownership in CRDL or CMED?

Which has preferable valuation and earnings, CRDL or CMED?

Summary

How does Cardiol Therapeutics compare to Canopy Growth?

Does the media favor WEED or CRDL?

Is WEED or CRDL more profitable?

Do analysts rate WEED or CRDL?

Which has stronger earnings and valuation, WEED or CRDL?

Which has more risk & volatility, WEED or CRDL?

Do insiders & institutionals believe in WEED or CRDL?

Summary

How does Cardiol Therapeutics compare to Fennec Pharmaceuticals?

Do institutionals & insiders have more ownership in CRDL or FRX?

Which has more risk & volatility, CRDL or FRX?

Does the media prefer CRDL or FRX?

Do analysts prefer CRDL or FRX?

Which has preferable valuation and earnings, CRDL or FRX?

Is CRDL or FRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools